NDA 021267 · Pf Prism Cv
Vfend
Voriconazole · Intravenous · Azole Antifungal
Last checked: Nov 20, 2026Latest source record: Feb 19, 2026 (newest FDA action)Source: Drugs@FDA, openFDA, CMS, ClinicalTrials.gov, PubMedMethods & limitations
First approved
2002
May 24, 2002
Approved uses
3
Original approval plus efficacy supplements
Registered trials
153
39 Phase 3, 14 recruiting
FAERS reports
30,722
28,342 serious, 8,951 with death reported
AI brief across all sources
Written by AI from the FDA, CMS, ClinicalTrials.gov, FAERS and PubMed data on this page, plus web searches for pricing, exclusivity and pending FDA decisions.
What it is approved for
From the label in effect Mar 20, 2026.
VFEND is an azole antifungal indicated for the treatment of adults and pediatric patients 2 years of age and older with: • Invasive aspergillosis ( 1.1 ) • Candidemia in non-neutropenics and other deep tissue Candida infections ( 1.2 ) • Esophageal candidiasis ( 1.3 ) • Serious fungal infections caused by Scedosporium apiospermum and Fusarium species including Fusarium solani , in patients intolerant of, or refractory to, other therapy ( 1.4 ) 1.1 Invasive Aspergillosis VFEND is indicated in adults and pediatric patients (2 years of age and older) for the treatment of invasive aspergillosis (IA). In clinical trials, the majority of isolates recovered were Aspergillus fumigatus . There was a small number of cases of culture-proven disease due to species of Aspergillus other than A. fumigatus [see Clinical Studies (14.1 , 14.5) and Microbiology (12.4) ] . 1.2 Candidemia in Non-neutropenic Patients and Other Deep Tissue Candida Infections VFEND is indicated in adults and pediatric patients (2 years of age and older) for the treatment of candidemia in non-neutropenic patients and the following Candida infections: disseminated infections in skin and infections in abdomen, kidney, bladder wall, and wounds [see Clinical Studies (14.2 , 14.5) and Microbiology (12.4) ] . 1.3 Esophageal Candidiasis VFEND is indicated in adults and pediatric patients (2 years of age and older) for the treatment of esophageal candidiasis (EC) [see Clinical Studies (14.3 , 14.5) and Microbiology (12.4) ] . 1.4 Scedosporiosis and Fusariosis VFEND is indicated for the treatment of serious fungal infections caused by Scedosporium apiospermum (asexual form of Pseudallescheria boydii ) and Fusarium spp. including Fusarium solani , in adults and pediatric patients (2 years of age and older) intolerant...
Mechanism: Voriconazole is an antifungal drug [see Microbiology (12.4) ].
Therapeutic areas: Infectious disease and vaccines
Approval history
Original approval and efficacy supplements (new uses, populations or doses), newest first, with FDA's letters and labels.
- Jan 29, 2019 Supplement 50 · Efficacy · priority review LabelLetter
- Dec 21, 2004 Supplement 9 · Efficacy LabelReviewLetter
- May 24, 2002 Original approval · Type 5 - New Formulation or New Manufacturer LetterPediatric Medical ReviewPediatric Medical Review
1 products under this application
- VFEND · VORICONAZOLE 200MG/VIAL · POWDER, INTRAVENOUS · Prescription · TE AP
Clinical trials
Interventional ClinicalTrials.gov studies with "Voriconazole" as an intervention, any sponsor and status, largest first.
- Study of Biomarker-Based Treatment of Acute Myeloid LeukemiaPivotal-lookingRecruiting
Beat AML, LLCAcademic, hospital or other
NCT03013998 · 3,000 participants (planned) · Start Nov 2016 · Primary completion Dec 2032
Drug: Samalizumab (BAML-16-001-S1); BI 836858 (BAML-16-001-S2) and 45 more · For: Previously Untreated Relapsed Refractory Acute Myeloid Leukemia
Sites: Phoenix, Arizona; Scottsdale, Arizona; Los Angeles, California · 31 sites in all
Sumitomo Pharma America, Inc.Industry
NCT04988555 · 606 participants (planned) · Start Feb 28, 2022 · Primary completion Jun 30, 2027
Drug: Enzomenib; azoles and 4 more · For: Leukemia, Myeloid, Acute; Leukemia, Lymphocytic, Acute; Multiple Myeloma and 1 more
Sites: Newport Beach, California; Palo Alto, California; Denver, Colorado · 104 sites in all
- Comparison of Fluconazole vs Voriconazole to Treat Fungal Infections for Blood and Marrow Transplants (BMT CTN 0101)Pivotal-lookingCompleted
Medical College of WisconsinAcademic, hospital or other
NCT00075803 · 600 participants · Start Nov 2003 · Primary completion Sep 2006
Drug: Fluconazole; Voriconazole · For: Lymphoma; Infection; Leukemia
Sites: Birmingham, Alabama; La Jolla, California; Stanford, California · 33 sites in all
- A Study of the Safety and Efficacy of Posaconazole Versus Voriconazole for the Treatment of Invasive Aspergillosis (MK-5592-069)Pivotal-lookingCompleted
Merck Sharp & Dohme LLCMerck & Co. (MRK)
NCT01782131 · 585 participants · Start Sep 25, 2013 · Primary completion Jul 10, 2019
Drug: Posaconazole; Voriconazole and 1 more · For: Fungal Infections; Invasive Pulmonary Aspergillosis
- Phase 1/1b Study of TLC-6740 in Healthy Subjects and Subjects With Obesity, With or Without DiabetesPivotal-lookingActive, not recruiting
OrsoBio, IncIndustry
NCT05822544 · 564 participants (planned) · Start Apr 22, 2023 · Primary completion Sep 2026
Drug: TLC-6740 Oral Solution; TLC-6740 Tablet and 2 more · For: Healthy Subjects; Obesity; Type 2 Diabetes
Sites: Auckland, New Zealand; Christchurch, New Zealand · 4 sites in all
- Isavuconazole (BAL8557) for Primary Treatment of Invasive AspergillosisPivotal-lookingCompleted
Astellas Pharma IncAstellas (ALPMY)
NCT00412893 · 527 participants · Start Mar 7, 2007 · Primary completion Mar 28, 2013
Drug: Isavuconazole; Voriconazole · For: Aspergillosis; Invasive Fungal Infection
Sites: Birmingham, Alabama; San Francisco, California; Chicago, Illinois · 107 sites in all
- Voriconazole Versus Itraconazole In Primary Prophylaxis Of Invasive Fungal Infection (IFI) In Subjects With Allogeneic Hematopoietic Stem Cell Transplants (HSCT)Pivotal-lookingCompleted
PfizerPfizer (PFE)
NCT00289991 · 489 participants · Start Mar 2006 · Primary completion Feb 2009
Drug: Itraconazole; Vfend - voriconazole · For: Antifungal Prophylaxis of Invasive Fungal Infections
Sites: Vancouver, Canada; Winnipeg, Canada; Hamilton, Canada · 49 sites in all
- Anidulafungin Plus Voriconazole Versus Voriconazole For The Treatment Of Invasive AspergillosisPivotal-lookingCompleted
PfizerPfizer (PFE)
NCT00531479 · 459 participants · Start Jul 2008 · Primary completion Apr 2011
Drug: voriconazole; anidulafungin and 1 more · For: Aspergillosis
Sites: Birmingham, Alabama; Little Rock, Arkansas; La Jolla, California · 107 sites in all
Most reported adverse reactions
FAERS reports naming this application or brand. Unverified reports, not rates; a report can name several drugs.
- drug ineffective4,336
- off label use2,510
- drug interaction2,408
- death1,481
- pyrexia1,455
- pneumonia1,359
- condition aggravated1,157
- bronchopulmonary aspergillosis1,066
- aspergillus infection943
- febrile neutropenia924
- respiratory failure865
- nausea796
FAERS reports by year
By the date FDA received the report.
View as table
| Year | Reports |
|---|---|
| 2004 | 315 |
| 2005 | 322 |
| 2006 | 418 |
| 2007 | 446 |
| 2008 | 429 |
| 2009 | 618 |
| 2010 | 855 |
| 2011 | 876 |
| 2012 | 1,097 |
| 2013 | 1,062 |
| 2014 | 1,063 |
| 2015 | 1,201 |
| 2016 | 1,422 |
| 2017 | 1,997 |
| 2018 | 2,244 |
| 2019 | 2,497 |
| 2020 | 2,370 |
| 2021 | 2,184 |
| 2022 | 2,258 |
| 2023 | 1,992 |
| 2024 | 1,898 |
| 2025 | 1,869 |
| 2026 | 1,288 |
Recalls
0 FDA enforcement reports for this application.
No recalls on record for this application.
Shortages
FDA's drug shortage list.
Not on FDA's shortage list.
Medicare spending
CMS Spending by Drug. Part D is pharmacy-dispensed; Part B is given in a clinic or hospital outpatient setting. Spending is before manufacturer rebates.
Part D: Vfend (Voriconazole)
2024 spending
$8K
Beneficiaries
12
19 claims
Per beneficiary
$635
$4.41 per unit
View as table
| Year | Spending |
|---|---|
| 2020 | $42,158 |
| 2021 | $13,420 |
| 2022 | $8,554 |
| 2023 | $10,102 |
| 2024 | $7,623 |
Published evidence
PubMed clinical trials, meta-analyses and systematic reviews, most relevant first.
- Isavuconazole versus voriconazole for primary treatment of invasive mould disease caused by Aspergillus and other filamentous fungi (SECURE): a phase 3, randomised-controlled, non-inferiority trial.
Maertens JA, Raad II, Marr KA, et al. · Lancet 2016 · Clinical Trial, Phase III, Comparative Study
- Interactions between herbal medicines and prescribed drugs: an updated systematic review.
Izzo AA, Ernst E · Drugs 2009 · Systematic Review
- Combination antifungal therapy for invasive aspergillosis: a randomized trial.
Marr KA, Schlamm HT, Herbrecht R, et al. · Ann Intern Med 2015 · Multicenter Study, Randomized Controlled Trial
- Cryptococcosis-a systematic review to inform the World Health Organization Fungal Priority Pathogens List.
Dao A, Kim HY, Garnham K, et al. · Med Mycol 2024 · Systematic Review
- Histoplasmosis: A systematic review to inform the World Health Organization of a fungal priority pathogens list.
Dao A, Kim HY, Halliday CL, et al. · Med Mycol 2024 · Systematic Review
- Aspergillus fumigatus-a systematic review to inform the World Health Organization priority list of fungal pathogens.
Morrissey CO, Kim HY, Duong TN, et al. · Med Mycol 2024 · Systematic Review
Sponsor: Pf Prism Cv
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.